Microbial expression of Exendin-4 analog and its efficacy in mice model
| Autor: | Divya Unnikrishnan, Bhargav Prasad Kodaganti, Yogendra Manjunath, Bharath R Shenoy, Sunit Maity, Vivek Halan, Maloy Ghosh, Bairavabalakumar Natarajan, Pavithra Mukunda, Sathyabalan Murugesan, Pravinkumar Dakshinamurthy, Veeresha Kamanagowda, Amol Maliwalave |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0106 biological sciences
0301 basic medicine Agonist Male endocrine system medicine.drug_class Drug Evaluation Preclinical Gene Expression Bioengineering Peptide hormone 01 natural sciences Applied Microbiology and Biotechnology law.invention 03 medical and health sciences Mice In vivo law 010608 biotechnology medicine Escherichia coli Animals Receptor Pharmacology chemistry.chemical_classification General Immunology and Microbiology business.industry Venoms digestive oral and skin physiology Biological activity General Medicine Recombinant Proteins Amino acid 030104 developmental biology chemistry Biochemistry Recombinant DNA Exenatide business Peptides hormones hormone substitutes and hormone antagonists Biotechnology medicine.drug |
| Zdroj: | Biologicals : journal of the International Association of Biological Standardization. 48 |
| ISSN: | 1095-8320 |
| Popis: | Exendin-4 is a GLP 1 agonist incretin-mimetic peptide hormone comprising 39 amino acids. Exenatide (Byetta®) is a chemically synthesized version of Exendin-4 with an additional C-terminal amidation. Exenatide acts as a GLP-1 receptor agonist. This paper illustrates the method adopted for cloning, fermentation and purification of recombinant Exendin-4 analog expressed in Escherichia coli. The biologically expressed analog was extensively characterized using different orthogonal methods to confirm their biological activity and physicochemical properties. It was observed that the expressed analog showed comparable functional properties as that of Byetta® irrespective of their modes of development. Further, in vivo efficacy of the recombinant Exendin-4 analog was studied in Oral Glucose Tolerance Test (OGTT) in mice models. Byetta® and Exendin-4 analog treated groups showed comparable glucose lowering activity in the OGTT model. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect